What is claimed is:

1. A *Crassocephalum crepidioides* extract obtainable from the process comprising the steps of:

(a) contacting *Crassocephalum crepidioides* plant with 70% ethanol to obtain a suspension;

(b) separating the suspension into a solid portion and a liquid portion, and then collecting the liquid portion to obtain a crude extract;

(c) diluting the crude extract to a 60% ethanol extract;

(d) mixing the 60% ethanol extract with microporous styrene-divinyl benzene resins;

(e) pouring the 60% ethanol extract and microporous styrene-divinyl benzene resin mixture into a column;

(f) washing the column with ethanol at a volume of about 2- to 10-fold to the volume of the column;

(g) eluting the column with a solvent of ethanol:ethyl acetate (1:1) or ethyl acetane and collecting the eluted fractions at different time intervals; and

(h) analyzing each eluted fraction and determining which one is enriched to 1,2-di-O-α-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG) and contains phytol as the *Crassocephalum crepidioides* extract.

2. The *Crassocephalum crepidioides* extract according claim 1, which has 7 main peaks at the retention times of 12.59 min, 12.893 min, 13.828 min, 14.158 min, 14.922 min, 15.455 min, and 16.478 min, respectively, when determined by HPLC at the following conditions:

Column: Symmetry Shield C18, 15 μm, 4.6 x 150 mm

Temperature: ambient

Elution: H_2O/CH_3CN gradient

Detection: UV 210 nm

Time (min)	Mobile phase (%)	
	H_2O	CH_3CN
0	35	65
10	3.5	96.5
20	3	97
22	0	100
27	0	100
28	35	65
35	35	65

3. A pharmaceutical composition comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical combination comprising a therapeutically effective amount of the *Crassocephalum crepidioides* extract according to claim 1 and a chemotherapeutic agent.

5. The pharmaceutical combination according to Claim 4, wherein the chemotherapeutic agent is selected from a antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

6. The pharmaceutical combination according to Claim 9, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

7. Use of the *Crassocephalum crepidioides* extract according to claim 1 the pharmaceutical composition according to claim 3, or the pharmaceutical combination according to claim 4 in the manufacture of a medicament for treating or preventing cancer in a subject in need.

8. Use of the *Crassocephalum crepidioides* extract according to claim 1or the pharmaceutical composition according to claim 3 in the manufacture of a medicament for treating or preventing cancer in a subject in need in combination with a chemotherapeutic agent.

9. The use according to claim 8, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

10. The use according to claim 8, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.

11. The *Crassocephalum crepidioides* extract according to claim 1, or the pharmaceutical composition according to claim 3 or the pharmaceutical combination according to any one of claims 4 to 6 for use in treating or preventing cancer.

12. The *Crassocephalum crepidioides* extract according to claim 1 or 2 or the pharmaceutical composition according to claim 3, or the pharmaceutical combination according to claim 4 for use in treating cancer.

13. The *Crassocephalum crepidioides* extract according to claim 1 or 2 or the pharmaceutical composition according to claim 3, or the pharmaceutical combination according to claim 4 for use in treating cancer, wherein the chemotherapeutic agent is selected from an antimetabolite, an alkylating agent, an anthracycline, an antibiotic, an antimitotic agent, and a proteasome inhibitor.

14. The *Crassocephalum crepidioides* extract according to claim 1 or 2 or the pharmaceutical composition according to claim 3, or the pharmaceutical combination according to claim 4 for use in treating cancer, wherein the chemotherapeutic agent is 5-fluorouracil (5-FU) or epirubicin.